Related Experiment Videos
Plasma MHPG in depression: effects of acute and chronic desipramine treatment
Abstract:
The effects of acute and chronic desmethylimipramine (DMI) administration on 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG) in plasma and urine were examined in eight depressed inpatients. DMI treatment induced an immediate and continuous highly significant reduction in plasma MHPG throughout the 30-day treatment period. This effect was not related to treatment response. In contrast to plasma MHPG, there was no uniform effect of DMI treatment on urinary MHPG. Chronic DMI treatment increased or did not change urinary MHPG in the three treatment responders and decreased urinary MHPG in five nonresponders. The correlation between plasma and urinary MHPG during the placebo period was not significant, and the effect of DMI treatment on the two measures differed markedly.
Insights
Desmethylipramine (DMI) significantly reduced plasma levels of 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG) in depressed patients. Urinary MHPG levels showed varied responses to DMI, differing between responders and non-responders.
Area of Science:
- Neuroscience
- Pharmacology
- Psychiatry
Background:
- Depression is often associated with altered noradrenergic neurotransmission.
- 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG) is a major metabolite of norepinephrine, serving as a biomarker for its activity.
- Desmethylimipramine (DMI) is a tricyclic antidepressant that affects noradrenergic pathways.
Purpose of the Study:
- To investigate the impact of acute and chronic desmethylimipramine (DMI) administration on MHPG levels in both plasma and urine.
- To determine if changes in MHPG correlate with treatment response in depressed patients.
Main Methods:
- Eight depressed inpatients were administered DMI over a 30-day period.
- Plasma and urine samples were collected to measure MHPG concentrations.
- Treatment response was assessed to correlate with MHPG changes.
Main Results:
- DMI administration led to an immediate and sustained significant reduction in plasma MHPG levels.
- This reduction in plasma MHPG was independent of the patient's treatment response.
- Urinary MHPG levels exhibited inconsistent changes; they increased or remained unchanged in responders, while decreasing in non-responders.
- Plasma and urinary MHPG showed no significant correlation during placebo, and DMI affected them differently.
Conclusions:
- Plasma MHPG is a sensitive indicator of DMI's acute and chronic effects on noradrenergic metabolism in depressed patients.
- Urinary MHPG is a less reliable biomarker for DMI's effects, with variable responses observed.
- The differential impact of DMI on plasma versus urinary MHPG highlights the complexity of antidepressant pharmacodynamics.